ArticleInternational journal of molecular sciences2020
Multi-Omics Integration Highlights the Role of Ubiquitination in CCl
Open access · goldAbstract read
In one paragraph
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Post-translational modification-regulating biomaterials for regeneration.Bioactive materials · 2026Review
- Yin-Dan-Ping-Gan Capsule Mitigates CCLPharmaceuticals (Basel, Switzerland) · 2026Article
- Extracellular vesicles from cyclic mice modulate liver transcriptome in estroupause mice independent of age.Molecular and cellular endocrinology · 2025Article
- Liver fibrosis and cirrhosis in the multi-omics era: mechanisms and therapeutic perspectives from human and animal models.Frontiers in cellular and infection microbiology · 2025Review
- Article
- Nedd4L signaling contributes to carbon tetrachloride-induced liver fibrosis in female mice and is associated with enteric dysbacteriosis.Gastroenterology report · 2025Article
- Neddylation inhibition prevents acetaminophen-induced liver damage by enhancing the anabolic cardiolipin pathway.Cell reports. Medicine · 2024Article
- The Upregulation of Leucine-Rich Repeat Containing 1 Expression Activates Hepatic Stellate Cells and Promotes Liver Fibrosis by Stabilizing Phosphorylated Smad2/3.International journal of molecular sciences · 2024Article
- FUNDC1 interacts with GPx4 to govern hepatic ferroptosis and fibrotic injury through a mitophagy-dependent manner.Journal of advanced research · 2024Article
- Tolerance of repeated toxic injuries of murine livers is associated with steatosis and inflammation.Cell death & disease · 2023Article
- F-box and WD repeat domain containing 7 inhibits the activation of hepatic stellate cells by degrading delta-like ligand 1 to block Notch signaling pathway.Open medicine (Warsaw, Poland) · 2023Article
- New phthalimide analog ameliorates CClSaudi journal of biological sciences · 2021Article
- Editorial of Special Issue "Protein Post-Translational Modifications in Signal Transduction and Diseases".International journal of molecular sciences · 2021Article
- Effect of Short-Term Tacrolimus Exposure on Rat Liver: An Insight into Serum Antioxidant Status, Liver Lipid Peroxidation, and Inflammation.Mediators of inflammation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 6 institutions in 1 country.
Maria Mercado-GómezLiver Disease Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.
Fernando Lopitz-OtsoaPrecision Medicine and Metabolism Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.ORCID 0000-0001-8452-6939
Mikel AzkargortaProteomics Platform, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), CIBERehd, ProteoRed-ISCII, 48160 Derio, Bizkaia, Spain.
Marina Serrano-MaciáLiver Disease Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.
Sofia Lachiondo-OrtegaLiver Disease Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.ORCID 0000-0003-1856-3664
Naroa Goikoetxea-UsandizagaLiver Disease Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.
Rubén Rodríguez-AgudoLiver Disease Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.
David Fernández-RamosPrecision Medicine and Metabolism Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.
Maider BizkarguenagaPrecision Medicine and Metabolism Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.ORCID 0000-0003-0988-2006
Virginia Gutiérrez-de JuanPrecision Medicine and Metabolism Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.
Benoît LectezDepartment of Biochemistry and Molecular Biology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.ORCID 0000-0001-9796-1606
Kerman AloriaProteomics Core Facility-SGIKER, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.ORCID 0000-0001-7268-7700
Jesus M ArizmendiDepartment of Biochemistry and Molecular Biology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
Jorge SimonLiver Disease Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.ORCID 0000-0003-0404-6244
Cristina AlonsoOWL Metabolomics, 48610 Derio, Bizkaia, Spain.ORCID 0000-0002-2019-678X
Juan J LozanoCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Matias A AvilaCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0001-6570-3557
Jesus M BanalesCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Jose J G MarinCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0003-1186-6849
Naiara BerazaLiver Disease Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.ORCID 0000-0003-0718-0940
José M MatoPrecision Medicine and Metabolism Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.
Félix ElortzaProteomics Platform, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), CIBERehd, ProteoRed-ISCII, 48160 Derio, Bizkaia, Spain.ORCID 0000-0001-8839-5438
Rosa BarrioUbiquitin-likes and Development Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.
James D SutherlandUbiquitin-likes and Development Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.ORCID 0000-0003-3229-793X
Ugo MayorDepartment of Biochemistry and Molecular Biology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
María L Martínez-ChantarLiver Disease Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.ORCID 0000-0002-6446-9911
Teresa C DelgadoLiver Disease Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain.ORCID 0000-0001-9204-581X
CIC bioGUNE · ESInstituto de Salud Carlos III · ESUniversity of the Basque Country · ESIkerbasque · ESOWL (Spain) · ESUniversidad de Salamanca · ES
Funding
PROBIOTICS IN NEONATAL GUT MICROBIAL ECOLOGYR03TW000601 · FIC · UNIVERSITY OF MARYLAND BALTIMORE · PI PANIGRAHI, PINAKI · 1996 to 1998
–Asociación Española Contra el Cáncer 2017-2018Caixa Scientific Foundation HR17-00601Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas EHD15PI05/2016Centro Internacional sobre el Envejecimiento 0348_CIE_6_EFundació la Marató de TV3 201916-31Instituto de Salud Carlos III PI16/00598Instituto de Salud Carlos III PI19/00819Junta de Castilla y León SA063P17Ministerio de Ciencia, Innovación y Universidades RTI2018-096759-A-100Ministerio de Ciencia, Innovación y Universidades SAF2017-87301-RMinisterio de Ciencia, Innovación y Universidades SAF2017-88041-RMinisterio de Economía, Industria y Competitividad, Gobierno de España SAF2016-75197-ROsasun Saila, Eusko Jaurlaritzako 2013111114Severo Ochoa Excellence Accreditation SEV-2016-0644University of Salamanca Foundation PC-TCUE18-20_051
Abstract
Liver fibrosis is the excessive accumulation of extracellular matrix proteins that occurs in chronic liver disease. Ubiquitination is a post-translational modification that is crucial for a plethora of physiological processes. Even though the ubiquitin system has been implicated in several human diseases, the role of ubiquitination in liver fibrosis remains poorly understood. Here, multi-omics approaches were used to address this. Untargeted metabolomics showed that carbon tetrachloride (CCl
Indexed as
GenomicsUbiquitinationAnimalsCarbon TetrachlorideDNA DamageDNA RepairHep G2 CellsHumansLiver CirrhosisLiver RegenerationMice, Inbred C57BLProliferating Cell Nuclear AntigenProteomeCarbon TetrachlorideProliferating Cell Nuclear AntigenProteomeDNA damage response (DDR)liver fibrosismetabolomicsproliferating cell nuclear antigen (PCNA)ubiquitination
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.